Skip to main content

Market Overview

Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'

Share:
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'

Jim Cramer, the host of CNBC’s “Mad Money,” has issued a warning to investors about the potential impact of weight loss drugs, such as Ozempic and Wegovy, on the food and beverage industry.

What Happened: Cramer cautioned investors on Monday about the growing popularity of GLP-1s, a new class of weight loss and diabetes drugs, such as Mounjaro and Zepbound, reported CNBC.

He advised investors to be cautious with food and beverage stocks, as the increasing use of these drugs could potentially lead to a significant decline in the industry. "Stay away from these food and beverage stocks because there will be a day, that day will come, when one of them finally admits they've been hurt by the GLP-1s, and that will take down every stock in the group," he said.

He also highlighted other factors that could contribute to a decrease in sales for food and beverage companies. While companies like PepsiCo Inc (NASDAQ:PEP) attribute their declining sales to a reduction in consumer disposable income, Cramer suggested that the decline could also be linked to rising prices or a shift in consumer preferences towards cannabis products.

"In the end, we just don't know what's the impact of the GLP-1s versus everything else," Cramer said. "However, you're fooling yourself if you think these drugs didn't play some sort of role."

See Also: Mark Zuckerberg Continues To Make A Killing With Meta’s Spectacular Surge By Selling Another $45M Worth Of Shares

Despite the uncertainty surrounding the future impact of these drugs on food stocks, Cramer emphasized that they will undoubtedly bring about significant changes in the market.

Why It Matters: The warning from Cramer comes at a time when the pharmaceutical industry is witnessing a surge in the popularity of weight loss drugs. Companies like Eli Lilly and Co (NYSE:LLY) have been expanding their market share with drugs like Tirzepatide.

Moreover, Cramer’s warning aligns with his previous insights into changing consumer behavior. He has previously suggested that the rise of cannabis is impacting alcohol sales, a trend that could also be influencing the food and beverage industry.

Read Next: Bitcoin Tastes $48,000 As Ethereum And Avalanche Follow, Led By Record ETF Asset Inflows: The Week In Retrospect

Image Via Shutterstock


Engineered by Benzinga Neuro, Edited by
Kaustubh Bagalkote


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


 

Related Articles (LLY + PEP)

View Comments and Join the Discussion!

Posted-In: eli lilly Kaustubh Bagalkote Mad MoneyAnalyst Color Equities News Health Care Markets

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com